Viral resistance and the selection of antiretroviral combinations.
about
Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication.In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidineAntiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activityConstruction and characterization of a temperature-sensitive human immunodeficiency virus type 1 reverse transcriptase mutantAnti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy.Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effectsDevelopment of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replicationThe Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets.Synthesis and anti-HIV activity of D- and L-thietanose nucleosides.New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitorsNovel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity.Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans.Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.
P2860
Q28343701-4281FD52-7A2A-4E55-B128-16B4FC066E14Q28344355-33123364-4259-4D58-A430-C601ED0FBB11Q28378892-455A93A6-81D1-4DF1-9CBC-33B05759E053Q28378894-9A77D63B-B722-408D-AEA4-1A198C18E4DCQ33782366-2EC5FDF2-B6E6-4767-8B81-46FD6D0CEEF9Q33977295-288D21D5-9D4C-4134-895D-054D41D1085DQ34485122-3D87E86B-D7F3-4099-BE52-BB474FCA5F79Q34691351-BAFEA2B1-413E-4F10-A383-432EA3C6D608Q36085386-5C7505DF-30CA-4B1F-97DA-AB28121DF7F1Q36104509-71E2EB36-9669-449A-86A6-6CC9D9A7DD38Q36870669-FA164B96-2784-4F2D-AF5C-3D53E3AA8BF6Q37262113-69592341-3DD2-40B9-BBAA-78C5E7237F82Q37734538-448D90AE-93B0-4C65-AE9C-17260BCC12C6Q39474118-1123A4B4-DC4E-4832-9EB6-360FF3A20E3DQ39578289-9B70A948-8D3D-4765-8EE5-C760349FE01A
P2860
Viral resistance and the selection of antiretroviral combinations.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Viral resistance and the selection of antiretroviral combinations.
@en
type
label
Viral resistance and the selection of antiretroviral combinations.
@en
prefLabel
Viral resistance and the selection of antiretroviral combinations.
@en
P1476
Viral resistance and the selection of antiretroviral combinations.
@en
P2093
P304
P407
P478
10 Suppl 1
P577
1995-01-01T00:00:00Z